symptomatic

[키워드] 1:1 95% CI addition adjusted Administered adverse events Analysis Anti-spike antibody assigned baseline carried clinical care clinical trials Complication COVID-19 death donors double-blind duration of symptoms Efficacy Efficacy and safety eligibility criteria end-organ Endpoint enrolled Evidence evidence of Factors finding greater Group allocation heterogeneity hospitalised hospitalised patient Hospitalised patients hyperimmune Immunoglobulin Immunotherapy Infection infusion Interaction International Intravenous immunoglobulin investigators mass mITT mITT analysis modified intention-to-treat Neutralising Antibodies neutralising antibody Organ failure outbreak outcome participant Passive Patient Phase 3 Placebo placebo group placebo-controlled placebo-controlled trial positive Primary outcome randomisation randomised randomised clinical trial Randomised trial Randomly ranged reaction receive Registered Remdesivir Research risk Saline SARS-CoV-2 serious infections significantly Standard of care stratified subgroup subgroups Symptom symptomatic therapy to define Treatment treatment of COVID-19 Trial trial participant trial participants Volume was measured were used with COVID-19
[DOI] 10.1016/S0140-6736(22)00101-5 PMC 바로가기 [Article Type] Clinical Trial